Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study ...
Are all cyclin-dependent kinases 4/6 inhibitors created equal? | npj Breast Cancer
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent. - ppt download
About IBRANCE® (palbociclib) | Safety Info
MONALEESA clinical program: a review of ribociclib use in different clinical settings | Future Oncology
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up | SpringerLink
Intrinsic molecular subtype and efficacy of palbociclib (PAL). (A)... | Download Scientific Diagram
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent. - ppt download
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind ...
IBRANCE® (palbociclib) + an AI | Primary Endpoint Data | Safety Info
Palbociclib in ER+ Breast Cancer - Breast Cancer - 2016 American Society of Clinical Oncology Annual Meeting - Oncology - Clinical Care Options
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent. - ppt download
IBRANCE® (palbociclib) + an AI | Preplanned PFS Analyses | Safety Info
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Figure 2 from PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer | PLOS ONE
Progression-free survival in the PALOMA-1 study (palbociclib +... | Download Scientific Diagram
Palbociclib and Letrozole in Advanced Breast Cancer | NEJM
Clinical Trial Summary | IBRANCE® (palbociclib) | Safety Info
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?
